SH3BGRL3 is a thioredoxin-family protein with a conserved TRX-like fold 1 that functions as a modulator of cellular redox and signaling pathways across multiple disease contexts. Structurally, SH3BGRL3 localizes to the cytoplasm and exhibits nuclear expression 1. Mechanistically, SH3BGRL3 facilitates glioblastoma tumorigenesis through a positive feedback loop with STAT3, wherein STAT3 directly transcribes SH3BGRL3, which subsequently activates STAT3 signaling to promote glioma stem cell self-renewal 2. In diabetic foot ulcers, SH3BGRL3 promotes endothelial cell proliferation, migration, and angiogenic capacity under hyperglycemic conditions 3. Clinically, SH3BGRL3 demonstrates disease biomarker potential across multiple conditions: it is upregulated in acute promyelocytic leukemia cells and associates with ATRA-induced differentiation pathways 1; serves as a potential molecular marker in primary Sjögren's syndrome 4; identifies early-onset Alzheimer's disease with superior specificity over late-onset disease 5; predicts postherpetic neuralgia risk following herpes zoster infection 6; correlates with reduced atrial fibrillation risk as a protective protein target 7; and exhibits elevated expression in early gastric cancer with associations to immune cell infiltration 8. These findings suggest SH3BGRL3 represents a pleiotropic biomarker with therapeutic potential in cancer, metabolic, and inflammatory diseases.